Find trials
Consejos para buscar

A Study of Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples

Overview

Información sobre este estudio

The purpose of this study is to collect vaginal and endometrial cell samples to study endometrial cancer.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Women at least 18 years of age.
  • Women who have had symptoms of abnormal uterine or post-menopausal bleeding, or abnormal ultrasound findings.
  • Thickened endometrial stripe.
  • Hereditary predisposition to endometrial cancer (e.g., HNPCC).
  • Women referred for endometrial biopsy to evaluate suspicion or high risk of endometrial cancer

Exclusion Criteria: 

  • Prior hysterectomy.
  • Pregnant women (there will be a verbal screen by the clinic nurse and the physician about a potential pregnancy and a pregnancy test may be conducted if there is any doubt).
  • Prior pelvic radiation. 
  • Cervical stenosis that renders Tao brush sampling impossible.

 

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Jamie Bakkum-Gamez, M.D.

Comunícate con nosotros para obtener el estatus más reciente

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Mark Sherman, M.D.

Cerrado para la inscripción

Contact information:

Laura Pacheco-Spann M.S.

(904) 953-0408

PachecoSpann.Laura@mayo.edu

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Paul Magtibay, M.D.

Comunícate con nosotros para obtener el estatus más reciente

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publicaciones

  • Endometrial carcinoma is the most distressing cause of abnormal vaginal bleeding. The intention of clinical management in the case of postmenopausal bleeding is to achieve an accurate diagnosis without overinvestigation. Read More on PubMed
  • To determine whether (1) black and white women with endometrial cancer were treated by different surgical specialties and in different types of hospitals and (2) differences in specialty and hospital type contributed to racial differences in survival. Read More on PubMed
  • Classifying endometrial hyperplasia (EH) according to the severity of glandular crowding (simple hyperplasia (SH) vs complex hyperplasia (CH)) and nuclear atypia (simple atypical hyperplasia (SAH) vs complex atypical hyperplasia (CAH)) should predict subsequent endometrial carcinoma risk, but data on progression are lacking. Our nested case-control study of EH progression included 138 cases, who were diagnosed with EH and then with carcinoma (1970-2003) at least 1 year (median, 6.5 years) later, and 241 controls, who were individually matched on age, date, and follow-up duration and counter-matched on EH classification. After centralised pathology panel and medical record review, we generated rate ratios (RRs) and 95% confidence intervals (CIs), adjusted for treatment and repeat biopsies. With disordered proliferative endometrium (DPEM) as the referent, AH significantly increased carcinoma risk (RR=14, 95% CI, 5-38). Risk was highest 1-5 years after AH (RR=48, 95% CI, 8-294), but remained elevated 5 or more years after AH (RR=3.5, 95% CI, 1.0-9.6). Progression risks for SH (RR=2.0, 95% CI, 0.9-4.5) and CH (RR=2.8, 95% CI, 1.0-7.9) were substantially lower and only slightly higher than the progression risk for DPEM. The higher progression risks for AH could foster management guidelines based on markedly different progression risks for atypical vs non-atypical EH. Read More on PubMed

Otros temas en investigación

.
CLS-20492228

Mayo Clinic Footer